A Review Of ITD-1
Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the primary-line treatment method of CML-CP. 5 hundred and nineteen individuals with recently diagnosed CML-CP have been randomly assigned to obtain dasatinib in a dose of a hundred mg the moment each day (259 patients) or imatinib in a dose of fo